Hollis-Eden Pharmaceuticals Inc. (HEPH) on Monday reported that the data from an on-going phase I/II clinical trial showed that Triolex is safe and well tolerated, and improves insulin sensitivity and lowers fasting glucose levels in obese insulin resistant subjects.
The phase I/II clinical trial is a 28-day double-blind placebo controlled clinical study, which was designed to study the safety, tolerability, pharmacokinetics and potential activity of Triolex at three dose levels when administered orally to obese insulin resistant subjects.
No serious adverse events or systemic toxicity were found from Triolex in all treated subjects, and all adverse events reported were mild and required no treatment, the company noted.
Hollis-Eden said it is now initiating a follow-on Phase II clinical trial to demonstrate efficacy in long-term glycemic control in type 2 diabetic patients by assessment of HbA1-c levels, an approvable end-point for diabetes.
HEPH is currently trading at $2.21, up 27 cents or 13.92%.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.